Brain tumors still lack effective treatments, and the mechanisms of tumor progression and therapeutic resistance are unclear. Multiple parameters affect cancer prognosis (e.g., type and grade, age, location, size, and genetic mutations) and election of suitable treatments is based on preclinical models and clinical data. However, most candidate drugs fail in human trials due to inefficacy. Cell lines and tissue culture plates do not provide physiologically relevant environments, and animal models are not able to adequately mimic characteristics of disease in humans. Therefore, increasing technological advances are focusing on in vitro and computational modeling to increase the throughput and predicting capabilities of preclinical systems. The extensive use of these therapeutic agents requires a more profound understanding of the tumor-stroma interactions, including neural tissue, extracellular matrix, blood-brain barrier, astrocytes and microglia. Microphysiological brain tumor models offer physiologically relevant vascularized ‘minitumors’ that can help deciphering disease mechanisms, accelerating the drug discovery and predicting patient's response to anticancer treatments. This article reviews progress in tumor-on-a-chip platforms that are designed to comprehend the particular roles of stromal cells in the brain tumor microenvironment.

Original languageEnglish (US)
Pages (from-to)220-229
Number of pages10
JournalBrain Research Bulletin
StatePublished - Sep 2021


  • Brain tumor
  • Disease models
  • Glioblastoma
  • Microfluidic devices
  • Organ-on-a-chip

ASJC Scopus subject areas

  • General Neuroscience


Dive into the research topics of 'Microphysiological systems to study tumor-stroma interactions in brain cancer'. Together they form a unique fingerprint.

Cite this